TABLE 6.
Sustained virological response outcomes of hepatitis C genotype 1 therapy in monoinfected individuals treated with hepatitis C protease inhibitors telaprevir and boceprevir
| Telaprevir | Boceprevir | |
|---|---|---|
| Naive patients | 75% versus 44%* | 63% versus 38%* |
| Naive with RVR | 92% (eRVR) | 88% (at week 4 of triple therapy) |
| Naive/cirrhosis | 62% versus 33% | 52% versus 38% |
| Previous relapser | 83% versus 24% | 75% versus 29% |
| Partial responder | 59% versus 15% | 52% versus 7% |
| Null responder | 29% versus 5% | 38% in a single-arm study |